Compare HCWB & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCWB | FTEL |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.7M |
| IPO Year | 2021 | 2023 |
| Metric | HCWB | FTEL |
|---|---|---|
| Price | $1.36 | $3.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 56.3K | ★ 335.7K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | ★ 48.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $422,026.00 | ★ $5,200,138.00 |
| Revenue This Year | $178.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.42 |
| 52 Week Low | $0.95 | $2.91 |
| 52 Week High | $41.20 | $1,427.20 |
| Indicator | HCWB | FTEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 73.02 |
| Support Level | $1.10 | $3.01 |
| Resistance Level | $1.35 | $3.50 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | 0.06 | 0.27 |
| Stochastic Oscillator | 89.07 | 83.36 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.